Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993).

Схожие документы

• Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).
  по: Goldstone, A, и др.
  Опубликовано: (1999)
• At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
  по: Ganzel, C, и др.
  Опубликовано: (2020)
• Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).
  по: Rowe, J, и др.
  Опубликовано: (2001)
• Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
  по: Paietta, E, и др.
  Опубликовано: (2008)
• Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
  по: Fielding, A, и др.
  Опубликовано: (2010)